89793-12-4

Basic information

• Product Name: ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE
• Synonyms: ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE;Ethyl 2-chloropyrimidine-5-carboxylate ,97%;2-chloro-pyrimidine-5-carboxylic acid ethyl ester;2-Chloro-5-(ethoxycarbonyl)pyrimidine;5-PyriMidinecarboxylic acid, 2-chloro-, ethyl ester;PyriMidin-5-carboxylic acid 2-chloro-, ethyl ester;2-Chloro-5-(ethoxycarbonyl)pyrimidine, 2-Chloro-5-(ethoxycarbonyl)-1,3-diazine;Ethyl 2-Chlorpyrimidine-5-carboxylate
• CAS NO: 89793-12-4
• Molecular Formula: C₇H₇ClN₂O₂
• Molecular Weight: 186.59568
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 89793-12-4.mol
• Article Data: 17

Chemical Properties

• Melting Point: 52-60℃
• Boiling Point: 80℃/760mm
• Flash Point: 143.816 °C
• Appearance: /Solid
• Density: 1.312 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Methanol
• PKA: -3.05±0.22(Predicted)
• CAS DataBase Reference: ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(89793-12-4)
• EPA Substance Registry System: ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(89793-12-4)

Safety Data

• Statements: 20/21/22
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 89793-12-4(Hazardous Substances Data)

Usage

Description

ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE is an organic compound that serves as an important intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is characterized by its chlorinated pyrimidine core and carboxylate ester functional group, which contribute to its reactivity and potential applications in chemical reactions.

Uses

Used in Pharmaceutical Industry:
ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE is used as a key intermediate in the synthesis of Retinoid X receptor (RXR) agonists. These RXR agonists are employed in the treatment of various types of cancers, including solid tumors and other malignancies. ETHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE plays a crucial role in the development of therapeutic agents that target and modulate the RXR pathway, leading to the regulation of gene expression and inhibition of cancer cell growth and proliferation.

InChI:InChI=1/C7H7ClN2O2/c1-2-12-6(11)5-3-9-7(8)10-4-5/h3-4H,2H2,1H3

Upstream product

• 2223-96-3 4-chloro-2-ethylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester 
• 879008-23-8 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 1086272-71-0 Ethyl (2E)-2-(ethoxymethyl)-3-methoxyacrylate 
• 33458-27-4 ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 2974-30-3 (Z)-ethyl-2-(ethoxymethyl)-3-methoxyacrylate 
• 763-69-9 ethyl 3-ethoxypropionate 
• 34780-29-5 3-oxo-propionic acid ethyl ester 
• 95928-49-7 2-hydroxy-pyrimidine-5-carboxylic acid ethyl ester 
• 95928-49-7 ethyl 2-oxo-1,2-dihydropyrimidine-5-carboxylate 
• 151323-66-9 ethyl 2-(ethylthio)pyrimidine-5-carboxylate 

Downstream Products

• 57401-76-0 2-aminopyrimidine-5-carboxylic acid ethyl ester 
• 304431-55-8 ethyl 2-[N-(3,5-di-tert-butylphenyl)amino] pyrimidine-5-carboxylate 
• 1224465-29-5 ethyl 2-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)pyrimidine-5-carboxylate 
• 110099-99-5 2-CHLOROPYRIMIDINE-5-CARBONYLCHLORIDE 
• 1213234-97-9 ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetate 
• 1235450-94-8 methyl 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-97-1 methyl 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235451-07-6 ethyl 2-(((2-(4-aminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-95-9 ethyl 2-(((2-(4-(acetamidomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-yl)Methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-96-0 2-(((2-(4-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylic acid 
• 1235450-98-2 ethyl 2-(((2-(3-(acetamidomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-yl)Methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 1235450-99-3 2-(((2-(3-(aminomethyl)phenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylic acid 
• 1235451-08-7 ethyl 2-(((2-(4-acetamidophenyl)-4-morpholinothieno-[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 
• 603965-77-1 ethyl 2-(piperazin-1-yl) pyrimidine-5-carboxylate 

Relevant articles and documents

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF

The Invention relates to the field of chemical medicines, and particularly to a purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof. The Invention provides a purinyl-N-hydroxyl pyrimidine formamide derivative with a st

Design and synthesis of novel androgen receptor antagonists via molecular modeling

Several androgen receptor (AR) antagonists are clinically prescribed to treat prostate cancer. Unfortunately, many patients become resistant to the existing AR antagonists. To overcome this, a novel AR antagonist candidate called DIMN was discovered by our research group in 2013. In order to develop compounds with improved potency, we designed novel DIMN derivatives based on a docking study and substituted carbons with heteroatom moieties. Encouraging in vitro results for compounds 1b, 1c, 1e, 3c, and 4c proved that the new design was successful. Among the newly synthesized compounds, 1e exhibited the strongest inhibitory effect on LNCaP cell growth (IC50= 0.35 μM) and also acted as a competitive AR antagonist with selectivity over the estrogen receptor (ER) and the glucocorticoid receptor (GR). A docking study of compound 1e fully supported these biological results. Compound 1e is considered to be a novel, potent and AR-specific antagonist for treating prostate cancer. Thus, our study successfully applied molecular modeling and bioisosteric replacement for hit optimization. The methods here provide a guide for future development of drug candidates through structure-based drug discovery and chemical modifications.